The Hub for Disease-Specific Clinical Information
Advertisement
Advertisement

Tumor-Lysis Syndrome in Patients With Genitourinary Cancers

By: Hillary Ojeda
Posted: Wednesday, April 3, 2019

Tumor-lysis syndrome is associated with a high mortality rate in patients with genitourinary cancers, according to a literature review and pooled analysis of published cases by Jue Wang, MD, FACP, of the University of Arizona Cancer Center, Phoenix, and colleagues. The findings on this rare but life-threatening complication were presented at the 2019 Genitourinary Cancers Symposium in San Francisco (Abstract 533).

“[Tumor-lysis syndrome] should be considered on the differential diagnosis, when evaluating renal failure and electrolyte derangement in patients with metastatic [genitourinary] cancers with liver metastases,” the investigators commented.

Data on 180 patients with tumor-lysis syndrome were collected; the median age of patients was 57 years, and the male-to-female ratio was 1.7. Of the total, the most common tumor sites were gastrointestinal (29%), genitourinary (22%), lung (16%), melanoma (11%), and breast (8.3%). Tumor-lysis syndrome was seen in 68% of patients resulting from cancer therapy, whereas it occurred spontaneously in the remaining patients. In 70% of the patients, liver metastasis was documented. High mortality was associated with older age and liver metastasis.

After the investigators compared clinical features, treatment, and outcomes, the morality rate of tumor-lysis syndrome was 70% in patients with renal cell carcinoma, 67% in those with urothelial carcinoma, 64% in those with prostate cancer, and 50% in patients with testicular germ cell tumor.

Disclosure: The study authors’ disclosure information may be found at coi.asco.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.